Mutant Amyloid-beta-sensitized dendritic cells as Alzheimer's disease vaccine

Journal of Neuroimmunology

Volumn 200, Issue 1-2, 2008, Pages 1-10

  Cao, Chuanhai ^a   Lin, Xiaoyang ^a   Zhang, Chi ^a   Wahi, Monika M ^a,b   Wefes, Inge ^c   Arendash, Gary ^a,b   Potter, Huntington ^a,c  

^a Byrd Alzheimer's Center and Research Institute   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer's disease; Amyloid beta peptide; Dendritic cells; Epitopes; Inflammation; Th1 Cells; Th2 cells; Vaccines

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; CYTOKINE; DENDRITIC CELL VACCINE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; MUTANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; INFLAMMATION; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; T LYMPHOCYTE; TRANSGENIC MOUSE;

ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; BONE MARROW; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MUTATION; PEPTIDE FRAGMENTS; TIME FACTORS;

EID: 50049114113     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.05.017     Document Type: Article

References (48)

1. Alzheimer's Association. Alzheimer's Disease Prevalence Rates Rise to More than Five Million in the United States Vol. 2007 (2007), Alzheimer's Association
2. Andrieu J.M., and Lu W. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results. J. Int. Med. 261 (2007) 123-131
3. Barrou B., Benoit G., Ouldkaci M., Cussenot O., Salcedo M., Agrawal S., Massicard S., Bercovici N., Ericson M.L., and Thiounn N. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol. Immunother. 53 (2004) 453-460
4. Bayer A.J., Bullock R., Jones R.W., Wilkinson D., Paterson K.R., Jenkins L., Millais S.B., and Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64 (2005) 94-101
5. Ciaramella A., Sanarico N., Bizzoni F., Moro M.L., Salani F., Scapigliati G., Spalletta G., Caltagirone C., and Bossu P. Amyloid beta peptide promotes differentiation of pro-inflammatory human myeloid dendritic cells. Neurobiol. Aging (2007)
6. Cohen S., Haimovich J., and Hollander N. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice. J. Immunother. 28 (2005) 461-466
7. Cribbs D.H., Ghochikyan A., Vasilevko V., Tran M., Petrushina I., Sadzikava N., Babikyan D., Kesslak P., Kieber-Emmons T., Cotman C.W., and Agadjanyan M.G. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. 15 (2003) 505-514
8. De Jonghe C., Zehr C., Yager D., Prada C.M., Younkin S., Hendriks L., Van Broeckhoven C., and Eckman C.B. Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol. Dis. 5 (1998) 281-286
9. Ethell D.W., Shippy D., Cao C., Cracchiolo J.R., Runfeldt M., Blake B., and Arendash G.W. A[beta]-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol. Dis. 23 (2006) 351-361
10. Fay J.W. Hematopoietic growth factors, dendritic cell biology, and vaccine therapy of cancer. Curr. Opin. Hematol. 9 (2002) 202-206
11. Gajewski T.F., Fallarino F., Ashikari A., and Sherman M. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin. Cancer Res. 7 (2001) 895s-901s
12. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., and Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
13. Hara H., Monsonego A., Yuasa K., Adachi K., Xiao X., Takeda S., Takahashi K., Weiner H.L., and Tabira T. Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J. Alzheimer's Dis. 6 (2004) 483-488
14. Hara H., Inoue M., Adachi K., Yonemitsu Y., Hasegawa M., Nabeshima T., and Tabira T. Mucosal immunotherapy for Alzheimer's disease with viral vectors. Nihon Shinkei Seishin Yakurigaku Zasshi 27 (2007) 53-56
15. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
16. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D.J., Hofmann M., Maddalena A., Papassotiropoulos A., and Nitsch R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
17. Jack A.M., Aydin N., Montenegro G., Alam K., and Wallack M. A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model. J. Surg. Res. 139 (2007) 164-169
18. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., and Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
19. Kutzler M.A., Cao C., Bai Y., Dong H., Choe P.Y., Saulino V., McLaughlin L., Whelan A., Choo A.Y., Weiner D.B., and Ugen K.E. Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice. Vaccine 24 (2006) 4630-4639
20. Loveland B.E., Zhao A., White S., Gan H., Hamilton K., Xing P.X., Pietersz G.A., Apostolopoulos V., Vaughan H., Karanikas V., Kyriakou P., McKenzie I.F., and Mitchell P.L. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin. Cancer Res. 12 (2006) 869-877
21. Manuel S.L., Rahman S., Wigdahl B., Khan Z.K., and Jain P. Dendritic cells in autoimmune diseases and neuroinflammatory disorders. Front. Biosci. 12 (2007) 4315-4335
22. Mittendorf E.A., Storrer C.E., Foley R.J., Harris K., Jama Y., Shriver C.D., Ponniah S., and Peoples G.E. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 106 (2006) 2309-2317
23. Monsonego A., Imitola J., Petrovic S., Zota V., Nemirovsky A., Baron R., Fisher Y., Owens T., and Weiner H.L. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5048-5053
24. Monsonego A., Maron R., Zota V., Selkoe D.J., and Weiner H.L. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10273-10278
25. Monsonego A., Zota V., Karni A., Krieger J.I., Bar-Or A., Bitan G., Budson A.E., Sperling R., Selkoe D.J., and Weiner H.L. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112 (2003) 415-422
26. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., and Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
27. Mosca P.J., Lyerly H.K., Clay T.M., Morse M.A., and Lyerly H.K. Dendritic cell vaccines. Front. Biosci. 12 (2007) 4050-4060
28. Mouri A., Noda Y., Hara H., Mizoguchi H., Tabira T., and Nabeshima T. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. Faseb J. 21 (2007) 2135-2148
29. Murakami K., Irie K., Morimoto A., Ohigashi H., Shindo M., Nagao M., Shimizu T., and Shirasawa T. Synthesis, aggregation, neurotoxicity, and secondary structure of various A beta 1-42 mutants of familial Alzheimer's disease at positions 21-23. Biochem. Biophys. Res. Commun. 294 (2002) 5-10
30. Nagaraj, S., Pisarev, V., Kinarsky, L., Sherman, S., Muro-Cacho, C., Altieri, D.C., Gabrilovich, D.I., 2007. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J. Immunother. (1997) 30, 169-179.
31. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9 (2003) 448-452
32. Nilsson L.N., Arendash G.W., Leighty R.E., Costa D.A., Low M.A., Garcia M.F., Cracciolo J.R., Rojiani A., Wu X., Bales K.R., Paul S.M., and Potter H. Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiol. Aging 25 (2004) 1153-1167
33. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., and Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003) 46-54
34. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M., and Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298 (2002) 1379
35. Satthaporn S., and Eremin O. Dendritic cells (II): role and therapeutic implications in cancer. J. R. Coll. Surg. Edinb. 46 (2001) 159-167
36. Schendel D.J. Dendritic cell vaccine strategies for renal cell carcinoma. Expert Opin. Biol. Ther. 7 (2007) 221-232
37. Seabrook T.J., Thomas K., Jiang L., Bloom J., Spooner E., Maier M., Bitan G., and Lemere C.A. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol. Aging 28 (2007) 813-823
38. Smit W.M., Rijnbeek M., van Bergen C.A., de Paus R.A., Vervenne H.A., van de Keur M., Willemze R., and Falkenburg J.H. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Hum. Immunol. 53 (1997) 216-223
39. Stills Jr. H.F. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J. 46 (2005) 280-293
40. Tjoa B.A., and Murphy G.P. Development of dendritic-cell based prostate cancer vaccine. Immunol. Lett. 74 (2000) 87-93
41. Toellner K.M., Luther S.A., Sze D.M., Choy R.K., Taylor D.R., MacLennan I.C., and Acha-Orbea H. T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J. Exp. Med. 187 (1998) 1193-1204
42. Van Nostrand W.E., Melchor J.P., Cho H.S., Greenberg S.M., and Rebeck G.W. Pathogenic effects of D23N Iowa mutant amyloid beta-protein. J. Biol. Chem. 276 (2001) 32860-32866
43. Wang S., Hong S., Wezeman M., Qian J., Yang J., and Yi Q. Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma. Front. Biosci. 12 (2007) 3566-3575
44. Watson D.J., Selkoe D.J., and Teplow D.B. Effects of the amyloid precursor protein Glu693 Ä Gln 'Dutch' mutation on the production and stability of amyloid beta-protein. Biochem. J. 340 Pt 3 (1999) 703-709
45. Wilcock D.M., Jantzen P.T., Li Q., Morgan D., and Gordon M.N. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144 (2007) 950-960
46. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., and Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 1 (2004) 24
47. Wu Q., Xia D., Carlsen S., and Xiang J. Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer. Curr. Gene Ther. 5 (2005) 237-247
48. Xiao B.G., Huang Y.M., and Link H. Dendritic cell vaccine design: strategies for eliciting peripheral tolerance as therapy of autoimmune diseases. BioDrugs 17 (2003) 103-111